Japanese Pharmaceutical Company Announces Transfer of Global Manufacturing for New Epilepsy Medicine to the UK

Japanese Pharmaceutical Company Announces Transfer of Global Manufacturing for New Epilepsy Medicine to the UK PR Newswire HATFIELD, England, September 25, 2012 HATFIELD, England, September 25, 2012 /PRNewswire/ -- Global solid dose manufacturing for Eisai's new epilepsy medicine ®Fycompa ▼ (perampanel) to start at £100 million UK based, purpose built, EMEA research and commercial regional headquarters Announcement comes one week after the UK and European launch of ®Fycompa (Eisai's new medicine for the treatment of epilepsy), which will be supplied across the world from the company's Hatfield site David Willetts (Minister for Universities and Science) formally opened UK Fycompa thsolid dose manufacturing facilities on Monday 24 September 2012 First global solid dose manufacture supply site outside of Japan for Fycompa Eisai has announced that their UK production facility has received its licence for solid dose manufacturing for their new first in class partial epilepsy treatment, ®Fycompa (perampanel). Discovered and developed in the UK and Japan, Fycompa was launched first globally in the UK on 12 September 2012. Manufacturing will take place at the company's European, Middle-East, Africa (EMEA) and Russia headquarters, situated in Hatfield, UK, representing a significant boost to both the local economy and the wider UK life-sciences environment.